In the latest session, Macrogenics Inc (NASDAQ: MGNX) closed at $16.81 down -7.33% from its previous closing price of $18.14. In other words, the price has decreased by -$1.33 from its previous closing price. On the day, 1755496 shares were traded.
Ratios:
For a deeper understanding of Macrogenics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.66 and its Current Ratio is at 5.68. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on February 14, 2024, Downgraded its rating to Neutral and sets its target price to $14 from $12 previously.
On December 20, 2023, Citigroup Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $7 to $13.
Guggenheim Upgraded its Neutral to Buy on November 07, 2023, while the target price for the stock was maintained at $12.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 07 when Bonvini Ezio sold 3,334 shares for $18.00 per share. The transaction valued at 60,012 led to the insider holds 71,334 shares of the business.
Peters Jeffrey Stuart sold 76,251 shares of MGNX for $1,258,142 on Feb 05. The Senior VP and General Counsel now owns 0 shares after completing the transaction at $16.50 per share. On Feb 01, another insider, Bonvini Ezio, who serves as the Sr VP, Research & CSO of the company, sold 13,316 shares for $15.00 each. As a result, the insider received 199,740 and left with 74,668 shares of the company.
Valuation Measures:
As of this moment, Macrogenics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.61 while its Price-to-Book (P/B) ratio in mrq is 5.38. Its current Enterprise Value per Revenue stands at 5.45 whereas that against EBITDA is 42.98.
Stock Price History:
Over the past 52 weeks, MGNX has reached a high of $18.85, while it has fallen to a 52-week low of $4.29. The 50-Day Moving Average of the stock is 12.78, while the 200-Day Moving Average is calculated to be 7.37.
Shares Statistics:
For the past three months, MGNX has traded an average of 928.43K shares per day and 1.07M over the past ten days. A total of 61.70M shares are outstanding, with a floating share count of 58.14M. Insiders hold about 6.27% of the company’s shares, while institutions hold 96.02% stake in the company. Shares short for MGNX as of Jan 31, 2024 were 8.34M with a Short Ratio of 8.98, compared to 7.73M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 13.44% and a Short% of Float of 16.42%.
Earnings Estimates
There are 10 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of $0.38 and a low estimate of -$0.37, while EPS last year was $0.21. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.31 and low estimates of -$0.62.
Analysts are recommending an EPS of between $0.72 and $0.22 for the fiscal current year, implying an average EPS of $0.38. EPS for the following year is -$1.87, with 9 analysts recommending between -$1.03 and -$2.71.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $31.88M this quarter.It ranges from a high estimate of $72.4M to a low estimate of $14.46M. As of the current estimate, Macrogenics Inc’s year-ago sales were $73.1M, an estimated decrease of -56.40% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $14.34M, a decrease of -41.50% over than the figure of -$56.40% in the same quarter last year. There is a high estimate of $22.7M for the next quarter, whereas the lowest estimate is $10.46M.
A total of 10 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $120.4M, while the lowest revenue estimate was $62.49M, resulting in an average revenue estimate of $80.1M. In the same quarter a year ago, actual revenue was $151.94M, down -47.30% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $75.5M in the next fiscal year. The high estimate is $137.34M and the low estimate is $19M. The average revenue growth estimate for next year is down -5.70% from the average revenue estimate for this year.
